Evidence map›Paper›PMID 33435902›Full record

ArticleBMC cancer2021

Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.

Xin-Yu Li, Jia-Qiang Li, Xue-Qun Luo, Xue-Dong Wu, Xin Sun, Hong-Gui Xu, Chang-Gang Li, Ri-Yang Liu, Xiao-Fei Sun, Hui-Qin Chen and 3 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. [Optimized treatment of childhood B-lineage acute lymphoblastic leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2023
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 1 country.

Xin-Yu LiDepartment of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
Jia-Qiang LiDepartment of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
Xue-Qun LuoThe First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
Xue-Dong WuNanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Xin SunGuangzhou Women and Children's Medical Center, Guangzhou, 510623, China.
Hong-Gui XuDepartment of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
Chang-Gang LiShenzhen Children's Hospital, Shenzhen, 518038, China.
Ri-Yang LiuHuizhou Municipal Central People's Hospital, Huizhou, 516001, China.
Xiao-Fei SunSun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Hui-Qin ChenThe Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510630, China.
Yu-Deng LinGuangdong General Hospital, Guangzhou, 510080, China.
Chi-Kong LiHong Kong Children Hospital and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, 999077, China.
Jian-Pei FangDepartment of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China. fangjpei@mail.sysu.edu.cn.
Sun Yat-sen Memorial Hospital · CNGuangdong General Hospital · CNGuangzhou Medical University · CNHuizhou Central People's Hospital · CNPrince of Wales Hospital · CNShenzhen Children's Hospital · CNSouthern Medical University · CNSun Yat-sen University · CNSun Yat-sen University Cancer Center · CNThe First Affiliated Hospital, Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognosis of childhood acute lymphoblastic leukemia (ALL) is optimistic with a 5-year event-free survival (EFS) rate of 70-85%. However, the major causes of mortality are chemotherapy toxicity, infection and relapse. The Guangdong (GD)-2008-ALL collaborative protocol was carried out to study the effect of reduced intensity on treatment related mortality (TRM) based on Berlin-Frankfurt-Münster (BFM) 2002 backbone treatment. The study was designed to elucidate whether the reduced intensity is effective and safe for children with ALL.

methodsThe clinical data were obtained from February 28, 2008 to June 30, 2016. A total of 1765 childhood ALL cases from 9 medical centers were collected and data were retrospectively analyzed. Patients were stratified into 3 groups according to bone marrow morphology, prednisone response, age, genotype, and karyotype information: standard risk (SR), intermediate risk (IR) and high risk (HR). For SR group, daunorubicin was decreased in induction IA while duration was reduced in Induction Ib (2 weeks in place of 4 weeks). Doses for CAM were same in all risk groups - SR patients received one CAM, others got two CAMs.

resultsThe 5-year and 8-year overall survival (OS), event-free survival (EFS) and cumulative incidence of relapse (CIR) were 83.5±0.9% and 83.1±1.0%, 71.9±1.1% and 70.9±1.2%, and 19.5±1.0% and 20.5±1.1%, respectively. The 2-year treatment-related mortality (TRM) was 5.2±0.5%. The 5-year and 8-year OS were 90.7±1.4% and 89.6±1.6% in the SR group, while the 5-year and 8-year EFS were 81.5±1.8% and 80.0±2.0%. In the SR group, 74 (15.2%) patients measured minimal residual disease (MRD) on Day 15 and Day 33 of induction therapy. Among them, 7 patients (9.46%) were MRD positive (≥ 0.01%) on Day 33. The incidence of relapse in the MRD Day 33 positive group (n=7) was 28.6%, while in the MRD Day 33 negative group (n=67) was 7.5% (p=0.129).

conclusionsThe results of GD-2008-ALL protocol are outstanding for reducing TRM in childhood ALL in China with excellent long term EFS. This protocol provided the evidence for further reducing intensity of induction therapy in the SR group according to the risk stratification. MRD levels on Day 15 and Day 33 are appropriate indexes for stratification.

Indexed as

AdolescentAntineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolCyclophosphamideCytarabineDaunorubicinFemaleFollow-Up StudiesHumansInfantMaleMercaptopurineNeoplasm Recurrence, LocalNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaCyclophosphamideCytarabineDaunorubicinMercaptopurinePrednisoneAcute lymphoblastic leukemiaChemotherapyChildrenReduced intensity multi-centric clinical study

Identifiers

PMID33435902
PMCPMC7805214
OpenAlexW3118754956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.